^
Association details:
| Biomarker: | ALK rearrangement + EML4-ALK fusion + CCDC148-ALK fusion + PKDCC-ALK fusion + VIT-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
A NSCLC patient with novel ALK fusion responded to crizotinib therapy after alectinib-induced interstitial lung disease
Published date:
10/09/2023
Excerpt:
A 54-year-old, non-smoking woman was diagnosed as stage ⅣB adenocarcinoma with widespread bone metastasis (cT4N2M1c) in our hospital. Immunohistochemistry (Ventana D5F3 antibody) result showed the presence of ALK rearrangement; and next-generation sequencing assay (NGS) indicated EML4-ALK fusion (E6:A20) with concurrent CCDC148-ALK (C1:A20), PKDCC-ALK (Pintergenic:A20)and VIT-ALK (V15:A20) fusions....The administration of a first-generation ALK inhibitor crizotinib was then initiated and the disease was stable for 25 months without recurrence of ILD.
DOI:
10.3724/zdxbyxb-2023-0319
